sildenafil

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sexual Dysfunctions, Psychological

Conditions

Sexual Dysfunctions, Psychological, Sexual Arousal Disorder

Trial Timeline

Jan 1, 2003 → Feb 1, 2004

NCT ID

NCT00746967

About sildenafil

sildenafil is a phase 2 stage product being developed by Pfizer for Sexual Dysfunctions, Psychological. The current trial status is completed. This product is registered under clinical trial identifier NCT00746967. Target conditions include Sexual Dysfunctions, Psychological, Sexual Arousal Disorder.

What happened to similar drugs?

3 of 9 similar drugs in Sexual Dysfunctions, Psychological were approved

Approved (3) Terminated (0) Active (6)

✅sildenafilPfizerApproved

✅AlfuzosinSanofiApproved

✅Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved

🔄DapoxetineJohnson & JohnsonPhase 3

🔄AVANAFIL + placeboSanofiPhase 3

🔄tibolone + estradiol-norethisteroneOrganonPhase 3

🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01897740	Pre-clinical	Completed	—	—	Pulmonary Arterial Hypertension
NCT01889966	Approved	Completed	Apr 1, 2013	Jan 1, 2015	Pulmonary Hypertension Associated With Connective Tissue Disease
NCT01642407	Approved	Completed	Aug 24, 2012	Mar 12, 2018	Pulmonary Arterial Hypertension
NCT01360671	Phase 2	Withdrawn	Mar 1, 2012	Apr 1, 2013	Persistent Pulmonary Hypertension of the Newborn
NCT01108900	Pre-clinical	Completed	Jul 1, 2010	Oct 1, 2011	Erectile Dysfunction
NCT00800592	Phase 1	Completed	Oct 1, 2008	Dec 1, 2008	Hypertension, Pulmonary
NCT00666198	Pre-clinical	Completed	May 1, 2008	Jun 1, 2015	Pulmonary Hypertension
NCT00768573	Pre-clinical	Completed	Jan 1, 2008	Jan 1, 2008	None Volunteer
NCT00625079	Approved	Withdrawn	Feb 1, 2007	Dec 1, 2009	Pulmonary Arterial Hypertension
NCT00249730	Approved	Completed	Oct 1, 2005	—	Impotence
NCT00245596	Approved	Completed	Oct 1, 2005	—	Impotence
NCT00746967	Phase 2	Completed	Jan 1, 2003	Feb 1, 2004	Sexual Dysfunctions, Psychological
NCT00145483	Approved	Completed	Jun 18, 2002	Nov 8, 2006	Meniere's Disease
NCT00375297	Approved	Completed	Jan 1, 2001	Jun 1, 2005	Sexual Dysfunction

Competing Products

18 competing products in Sexual Dysfunctions, Psychological

See all competitors

Product	Company	Stage	Hype Score
Dapoxetine	Johnson & Johnson	Phase 3	40
Gardasil Vaccine	Merck	Pre-clinical	26
sildenafil	Pfizer	Approved	43
CP-866,087 + CP-866,087 + CP-866,087 + Placebo	Pfizer	Phase 2	35
PF-00446687 + Placebo	Pfizer	Phase 2	35
Bremelanotide	Pfizer	Phase 2	35
Sildenafil 100 mg + Placebo	Pfizer	Phase 2	35
Alfuzosin	Sanofi	Approved	43
AVANAFIL + placebo	Sanofi	Phase 3	40
Levitra (Vardenafil, BAY38-9456) + Placebo	Bayer	Approved	40
Placebo + 0.5 mgTestosterone + 10 mg Buspirone	Brain Biotech	Phase 2	25
Placebo + Testosterone + Buspirone hydrochloride	Brain Biotech	Phase 2	25
Placebo + Sildenafil + Testosterone	Brain Biotech	Phase 2	25
tibolone + estradiol-norethisterone	Organon	Phase 3	34
Bremelanotide + Placebo	Palatin Technologies	Phase 3	30
bremelanotide	Palatin Technologies	Phase 2	25
Bremelanotide	Palatin Technologies	Phase 3	30
EVO100 + Placebo	Evofem Biosciences	Phase 3	30